1999 keystone symposium on B lymphocyte biology and disease: B cell malignancy II session.
Levy
R
R
Division of Oncology, M 207 Stanford Medical Center, Stanford, CA, USA. levy@leland.stanford.edu
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D018951:Antigens, CD20 / Q000276:immunology; D023201:CD40 Ligand; D019496:Cancer Vaccines / Q000627:therapeutic use; D006801:Humans; D007130:Immunoglobulin Idiotypes / Q000276:immunology; D008213:Lymphocyte Activation; D016393:Lymphoma, B-Cell / Q000276:immunology / Q000628:therapy*; D008224:Lymphoma, Follicular / Q000276:immunology / Q000628:therapy; D008562:Membrane Glycoproteins / Q000494:pharmacology; D012074:Remission Induction; D014407:Tumor Cells, Cultured; D014611:Vaccination; D019444:Vaccines, DNA / Q000627:therapeutic use
D000911:Antibodies, Monoclonal; D018951:Antigens, CD20; D019496:Cancer Vaccines; D007130:Immunoglobulin Idiotypes; D008562:Membrane Glycoproteins; D019444:Vaccines, DNA; D023201:CD40 Ligand